perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”10.21508/1027-4065-2024-69-1-58-65perinatology-1939Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESСравнительная оценка кишечной микробиоты при аутоиммунных и неаутоиммунных заболеваниях печени у детейComparative assessment of intestinal microbiota in autoimmune and non-autoimmune liver diseases in childrenhttps://orcid.org/0000-0001-8837-9243НикитинА. В.NikitinA. V.

Артем Вячеславович Никитин, к. м. н., вед. науч. сотр., асс.

отдел гастроэнтерологии

факультет дополнительного профессионального образования

кафедра гастроэнтерологии

125412

ул. Талдомская, д. 2

Москва

Moscow

https://orcid.org/0000-0002-5413-9599ВолынецГ. В.VolynetsG. V.

Галина Васильевна Волынец, д. м. н., гл. науч. сотр., рук. отдела

отдел гастроэнтерологии

125412

ул. Талдомская, д. 2

Москва

Moscow

volynec_g@mail.ruhttps://orcid.org/0000-0003-4905-2373ПотаповА. С.PotapovA. S.

Александр Сергеевич Потапов,  д. м. н., проф., гл. науч. сотр., зав. отделением

гастроэнтерологическое отделение с гепатологической группой

119296

Ломоносовский проспект, д. 2, стр. 1

Москва

Moscow

https://orcid.org/0000-0002-6271-5218ДудуричВ. В.DudurichV. V.

Василиса Валерьевна Дудурич, рук. отдела

отдел «Микробиом»

199106

Большой проспект Васильевского острова, 90, корп. 2

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-4479-3095ДаниловЛ. Г.DanilovL. G.

Лаврентий Глебович Данилов, биоинформатик лаборатории, мл. науч. сотр.

кафедра генетики и биотехнологии

199106

Большой проспект Васильевского острова, 90, корп. 2

Санкт-Петербург

St. Petersburg

ОСП «Научно-исследовательский клинический институт педиатрии и детской хирургии им. академика Ю.Е. Вельтищева» (Институт Вельтищева) ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияVeltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University; Pirogov Russian National Research Medical UniversityRussian FederationФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава РоссииРоссияNational Medical Research Center for Children’s HealthRussian FederationМедико-генетический центр «CERBALAB»РоссияMedical Genetic Center CERBALABRussian FederationМедико-генетический центр «CERBALAB»; ФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияMedical Genetic Center CERBALAB; Saint Petersburg State UniversityRussian Federation2024070320246915865Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20242024Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/1939

   Влияние кишечной микробиоты на развитие различных заболеваний вызывает огромный интерес исследователей. Исследования показали, что у пациентов с хроническими заболеваниями печени доминирующими таксонами кишечной микробиоты были Bifidobacterium longum, Bifidobacterium adolescentis, Blautia massiliensis, а у здоровых детей — Neisseria flavescens. Сравнительный анализ данных о таксономическом разнообразии кишечной микробиоты при аутоиммунных и неаутоиммунных заболеваниях печени у детей отсутствует.

   Цель исследования

   Цель исследования. Изучение различий в таксономическом разнообразии фекальной микробиоты у пациентов с аутоиммунными и неаутоиммунными заболеваниями печени, а также оценка потенциальных биомаркеров ампликонов гена 16S рРНК при этих заболеваниях путем сравнения таксономического состава.

   Материалы и методы

   Материалы и методы. Проведен метагеномный анализ кишечной микробиоты 24 детей с хроническими заболеваниями печени (средний возраст 10,3 ± 4,7 года) с выделением региона гена 16S рРНК. В группу вошли 18 детей с аутоиммунными заболеваниями печени и 6 детей с неаутоиммунными заболеваниями печени.

   Результаты

   Результаты. Выявлено 684 вида микроорганизмов в исследуемых образцах кала пациентов. Анализ показал, что в образцах кала детей с аутоиммунными заболеваниями печени доминирующих таксонов не выявлено, а у пациентов с неаутоиммунными заболеваниями печени доминирующим таксонами были Veillonella dispar, Veillonella parvula, Cloacibacillus porcorum, Prevotella histicola и Bacteroides eggerthii.

   Заключение

   Заключение. Выявлены различия в составе кишечной микробиоты у детей с аутоиммунными и неаутоиммунными заболеваниями печени.

   The influence of the gut microbiota on the development of various diseases is of great interest to researchers. The conducted studies showed that in patients with chronic liver diseases, the dominant taxa of the gut microbiota were Bifidobacterium longum, Bifidobacterium adolescentis, Blautia massiliensis, and in healthy children — Neisseria flavescens. There is no comparative analysis of data on the taxonomic diversity of the intestinal microbiota in autoimmune and non-autoimmune liver diseases in children.

   Purpose

   Purpose. To investigate differences in the taxonomic diversity of fecal microbiota in patients with autoimmune and non-autoimmune liver diseases, as well as to evaluate potential biomarkers of 16S rRNA gene amplicons in these diseases by comparing the taxonomic composition.

   Material and methods

   Material and methods. A metagenomic analysis of the intestinal microbiota of 24 children with chronic liver diseases (mean age 10,3 ± 4,7 years) was carried out with the isolation of the 16S rRNA gene region. The group included 18 children with autoimmune liver diseases and 6 children with non-autoimmune liver diseases.

   Results

   Results. The conducted study revealed 684 types of microorganisms in the studied samples of patients’ feces. The analysis of the conducted studies showed that no dominant taxa were found in the fecal samples of children with autoimmune liver diseases, while Veillonella dispar, Veillonella parvula, Cloacibacillus porcorum, Prevotella histicola and Bacteroides eggerthii were the dominant taxa in patients with non-autoimmune liver diseases.

   Conclusion

   Conclusion. Studies have shown differences in the composition of the gut microbiota in children with autoimmune and non-autoimmune liver diseases.

детикишечная микробиотааутоиммунные болезни печенинеаутоиммунные болезни печениchildrengut microbiotaautoimmune liver diseasesautoimmune liver diseasesИсследование выполнено при частичной финансовой поддержке «Биокодекс Микробиота фонд», Национальный грант 2021, РоссияThe study was carried out with partial financial support from the Biocodex Microbiota Foundation, National Grant 2021, RussiaReferencesHe Y., Wu W., Zheng H.M., Li P., McDonald D., Sheng H.F. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med 2018; 24(10): 1532–1535. DOI: 10.1038/s41591–018–0164-xHe Y., Wu W., Zheng H.M., Li P., McDonald D., Sheng H.F. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med 2018; 24(10): 1532–1535. DOI: 10.1038/s41591–018–0164-xHuttenhower C., Gevers D., Knight R., Abubucker S., Badger J.H., Chinwalla A.T. et al. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486(7402): 207–214. DOI: 10.1038/nature11234Huttenhower C., Gevers D., Knight R., Abubucker S., Badger J.H., Chinwalla A.T. et al. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486(7402): 207–214. DOI: 10.1038/nature11234David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505(7484): 559–563. DOI: 10.1038/nature12820David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505(7484): 559–563. DOI: 10.1038/nature12820Sonnenburg E.D., Smits S.A., Tikhonov M., Higginbottom S.K., Wingreen N.S., Sonnenburg J.L. Diet-induced extinctions in the gut microbiota compound over generations. Nature 2016; 529(7585): 212–215. DOI: 10.1038/nature16504Sonnenburg E.D., Smits S.A., Tikhonov M., Higginbottom S.K., Wingreen N.S., Sonnenburg J.L. Diet-induced extinctions in the gut microbiota compound over generations. Nature 2016; 529(7585): 212–215. DOI: 10.1038/nature16504Modi S.R., Collins J.J., Relman D.A. Antibiotics and the gut microbiota. Clin Invest 2014; 124(10): 4212–4218. DOI: 10.1172/JCI72333Modi S.R., Collins J.J., Relman D.A. Antibiotics and the gut microbiota. Clin Invest 2014; 124(10): 4212–4218. DOI: 10.1172/JCI72333Maurice C.F., Haiser H.J., Turnbaugh P.J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013; 152(1–2): 39–50. DOI: 10.1016/j.cell.2012.10.052Maurice C.F., Haiser H.J., Turnbaugh P.J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013; 152(1–2): 39–50. DOI: 10.1016/j.cell.2012.10.052Sonnenburg J.L., Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016; 535(7610): 56–64. DOI: 10.1038/nature18846Sonnenburg J.L., Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016; 535(7610): 56–64. DOI: 10.1038/nature18846Jones R.M., Neish A.S. Gut Microbiota in Intestinal and Liver Disease. Annu Rev Pathol 2021; 16: 251–275. DOI: 10.1146/annurev-pathol-030320–095722Jones R.M., Neish A.S. Gut Microbiota in Intestinal and Liver Disease. Annu Rev Pathol 2021; 16: 251–275. DOI: 10.1146/annurev-pathol-030320–095722Xu X.R., Liu C.Q., Feng B.S., Liu Z.J. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014; 20(12): 3255–3264. DOI: 10.3748/wjg.v20.i12.3255Xu X.R., Liu C.Q., Feng B.S., Liu Z.J. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014; 20(12): 3255–3264. DOI: 10.3748/wjg.v20.i12.3255Carrière J., Darfeuille-Michaud A., Nguyen H.T. Infectious etiopathogenesis of Crohn’s disease. World J Gastroenterol 2014; 20(34): 12102–12117. DOI: 10.3748/wjg.v20.i34.12102Carrière J., Darfeuille-Michaud A., Nguyen H.T. Infectious etiopathogenesis of Crohn’s disease. World J Gastroenterol 2014; 20(34): 12102–12117. DOI: 10.3748/wjg.v20.i34.12102Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009; 361(21): 2066–2078. DOI: 10.1056/NEJMra0804647Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009; 361(21): 2066–2078. DOI: 10.1056/NEJMra0804647Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573–621. DOI: 10.1146/annurev-immunol-030409–101225Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573–621. DOI: 10.1146/annurev-immunol-030409–101225Adolph T.E., Grander C., Moschen A.R., Tilg H. Liver-Microbiome Axis in Health and Disease. Trends Immunol 2018; 39(9): 712–723. DOI: 10.1016/j.it.2018.05.002Adolph T.E., Grander C., Moschen A.R., Tilg H. Liver-Microbiome Axis in Health and Disease. Trends Immunol 2018; 39(9): 712–723. DOI: 10.1016/j.it.2018.05.002Kummen M., Holm K., Anmarkrud J.A., Nygård S., Vesterhus M., Høivik M.L. et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 2017; 66(4): 611–619. DOI: 10.1136/gutjnl-2015–310500Kummen M., Holm K., Anmarkrud J.A., Nygård S., Vesterhus M., Høivik M.L. et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 2017; 66(4): 611–619. DOI: 10.1136/gutjnl-2015–310500Sabino J., Vieira-Silva S., Machiels K., Joossens M., Falony G., Ballet V. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 2016; 65(10): 1681–1689. DOI: 10.1136/gutjnl-2015–311004Sabino J., Vieira-Silva S., Machiels K., Joossens M., Falony G., Ballet V. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 2016; 65(10): 1681–1689. DOI: 10.1136/gutjnl-2015–311004Tang R., Wei Y., Li Y., Chen W., Chen H., Wang Q. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018; 67(3): 534–541. DOI: 10.1136/gutjnl-2016–313332Tang R., Wei Y., Li Y., Chen W., Chen H., Wang Q. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018; 67(3): 534–541. DOI: 10.1136/gutjnl-2016–313332Tripathi A., Debelius J., Brenner D.A., Karin M., Loomba R., Schnabl B. et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018; 15(7): 397–411. DOI: 10.1038/s41575–018–0011-zTripathi A., Debelius J., Brenner D.A., Karin M., Loomba R., Schnabl B. et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018; 15(7): 397–411. DOI: 10.1038/s41575–018–0011-zManfredo Vieira S., Hiltensperger M., Kumar V., Zegarra-Ruiz D., Dehner C., Khan N. et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018; 359(6380): 1156–1161. DOI: 10.1126/science.aar7201Manfredo Vieira S., Hiltensperger M., Kumar V., Zegarra-Ruiz D., Dehner C., Khan N. et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018; 359(6380): 1156–1161. DOI: 10.1126/science.aar7201Yuksel M., Wang Y., Tai N., Peng J., Guo J., Beland K. et al. A novel «humanized mouse» model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 2015; 62(5): 1536–1550. DOI: 10.1002/hep.27998Yuksel M., Wang Y., Tai N., Peng J., Guo J., Beland K. et al. A novel «humanized mouse» model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 2015; 62(5): 1536–1550. DOI: 10.1002/hep.27998Klaassen C.D., Cui J.Y. Review: mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos 2015; 43(10): 1505–1521. DOI: 10.1124/dmd.115.065698Klaassen C.D., Cui J.Y. Review: mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos 2015; 43(10): 1505–1521. DOI: 10.1124/dmd.115.065698Dawson P.A., Karpen S.J. Intestinal transport and metabolism of bile acids. J Lipid Res 2015; 56(6): 1085–1099. DOI: 10.1194/jlr.R054114Dawson P.A., Karpen S.J. Intestinal transport and metabolism of bile acids. J Lipid Res 2015; 56(6): 1085–1099. DOI: 10.1194/jlr.R054114Sayin S.I., Wahlström A., Felin J., Jäntti S., Marschall H.U., Bamberg K. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17(2): 225–235. DOI: 10.1016/j.cmet.2013.01.003Sayin S.I., Wahlström A., Felin J., Jäntti S., Marschall H.U., Bamberg K. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17(2): 225–235. DOI: 10.1016/j.cmet.2013.01.003Jia W., Xie G., Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol 2018; 15(2): 111–128. DOI: 10.1038/nrgastro.2017.119Jia W., Xie G., Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol 2018; 15(2): 111–128. DOI: 10.1038/nrgastro.2017.119Wahlström A., Sayin S.I., Marschall H.U., Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 2016; 24(1): 41–50. DOI: 10.1016/j.cmet.2016.05.005Wahlström A., Sayin S.I., Marschall H.U., Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 2016; 24(1): 41–50. DOI: 10.1016/j.cmet.2016.05.005Spadoni I., Zagato E., Bertocchi A., Paolinelli R., Hot E., Di Sabatino A. et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science 2015; 350(6262): 830–834. DOI: 10.1126/science.aad0135Spadoni I., Zagato E., Bertocchi A., Paolinelli R., Hot E., Di Sabatino A. et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science 2015; 350(6262): 830–834. DOI: 10.1126/science.aad0135Balmer M.L., Slack E., de Gottardi A., Lawson M.A., Hapfelmeier S., Miele L. et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med 2014; 6(237): 237ra66. DOI: 10.1126/scitranslmed.3008618Balmer M.L., Slack E., de Gottardi A., Lawson M.A., Hapfelmeier S., Miele L. et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med 2014; 6(237): 237ra66. DOI: 10.1126/scitranslmed.3008618Chen F., Stappenbeck T.S. Microbiome control of innate reactivity. Curr Opin Immunol 2019; 56: 107–113. DOI: 10.1016/j.coi.2018.12.003Chen F., Stappenbeck T.S. Microbiome control of innate reactivity. Curr Opin Immunol 2019; 56: 107–113. DOI: 10.1016/j.coi.2018.12.003Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J., Holmes S.P. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 2016; 13(7): 581–583. DOI:10.1038/nmeth.3869Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J., Holmes S.P. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 2016; 13(7): 581–583. DOI:10.1038/nmeth.3869Wang E.T., Moyzis R.K. Genetic evidence for ongoing balanced selection at human DNA repair genes ERCC8, FANCC, and RAD51C. Mutat Res 2007; 616(1–2): 165–174. DOI: 10.1016/j.mrfmmm.2006.11.030Wang E.T., Moyzis R.K. Genetic evidence for ongoing balanced selection at human DNA repair genes ERCC8, FANCC, and RAD51C. Mutat Res 2007; 616(1–2): 165–174. DOI: 10.1016/j.mrfmmm.2006.11.030Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 2013; 41(Database issue): D590–D596. DOI: 10.1093/nar/gks1219Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 2013; 41(Database issue): D590–D596. DOI: 10.1093/nar/gks1219Blander J.M., Longman R.S., Iliev I.D., Sonnenberg G.F., Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol 2017; 18(8): 851–860. DOI: 10.1038/ni.3780Blander J.M., Longman R.S., Iliev I.D., Sonnenberg G.F., Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol 2017; 18(8): 851–860. DOI: 10.1038/ni.3780Clemente J.C., Manasson J., Scher J.U. The role of the gut microbiome in systemic inflammatory disease. BMJ 2018; 360: j5145. DOI: 10.1136/bmj.j5145Clemente J.C., Manasson J., Scher J.U. The role of the gut microbiome in systemic inflammatory disease. BMJ 2018; 360: j5145. DOI: 10.1136/bmj.j5145Gevers D., Kugathasan S., Denson L.A., Vázquez-Baeza Y., Van Treuren W., Ren B. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014; 15(3): 382–392. DOI: 10.1016/j.chom.2014.02.005Gevers D., Kugathasan S., Denson L.A., Vázquez-Baeza Y., Van Treuren W., Ren B. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014; 15(3): 382–392. DOI: 10.1016/j.chom.2014.02.005Kummen M., Hov J.R. The gut microbial influence on cholestatic liver disease. Liver Int 2019; 39(7): 1186–1196. DOI: 10.1111/liv.14153Kummen M., Hov J.R. The gut microbial influence on cholestatic liver disease. Liver Int 2019; 39(7): 1186–1196. DOI: 10.1111/liv.14153Nakamoto N., Sasaki N., Aoki R., Miyamoto K., Suda W., Teratani T. et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 2019; 4(3): 492–503. DOI: 10.1038/s41564–018–0333–1Nakamoto N., Sasaki N., Aoki R., Miyamoto K., Suda W., Teratani T. et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 2019; 4(3): 492–503. DOI: 10.1038/s41564–018–0333–1Liao L., Schneider K.M., Galvez E.J.C., Frissen M., Marschall H.U., Su H. et al. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. Gut 2019; 68(8): 1477–1492. DOI: 10.1136/gutjnl-2018–316670Liao L., Schneider K.M., Galvez E.J.C., Frissen M., Marschall H.U., Su H. et al. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. Gut 2019; 68(8): 1477–1492. DOI: 10.1136/gutjnl-2018–316670Zhao S., Gong Z., Zhou J., Tian C., Gao Y., Xu C. et al. Deoxycholic Acid Triggers NLRP3 Inflammasome Activation and Aggravates DSS-Induced Colitis in Mice. Front Immunol 2016; 7: 536. DOI: 10.3389/fimmu.2016.00536Zhao S., Gong Z., Zhou J., Tian C., Gao Y., Xu C. et al. Deoxycholic Acid Triggers NLRP3 Inflammasome Activation and Aggravates DSS-Induced Colitis in Mice. Front Immunol 2016; 7: 536. DOI: 10.3389/fimmu.2016.00536Deng X., Li Z., Li G., Li B., Jin X., Lyu G. Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy. Front Microbiol 2018; 9: 1607. DOI: 10.3389/fmicb.2018.01607Deng X., Li Z., Li G., Li B., Jin X., Lyu G. Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy. Front Microbiol 2018; 9: 1607. DOI: 10.3389/fmicb.2018.01607Kasai C., Sugimoto K., Moritani I., Tanaka J., Oya Y., Inoue H. et al. Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncol Rep 2016; 35(1): 325–33. DOI: 10.3892/or.2015.4398Kasai C., Sugimoto K., Moritani I., Tanaka J., Oya Y., Inoue H. et al. Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncol Rep 2016; 35(1): 325–33. DOI: 10.3892/or.2015.4398Matera G., Muto V., Vinci M., Zicca E., Abdollahi-Roodsaz S., van de Veerdonk F.L. et al. Receptor recognition of and immune intracellular pathways for Veillonella parvula lipopoly-saccharide. Clin Vaccine Immunol 2009; 16(12): 1804–1809. DOI: 10.1128/CVI.00310–09Matera G., Muto V., Vinci M., Zicca E., Abdollahi-Roodsaz S., van de Veerdonk F.L. et al. Receptor recognition of and immune intracellular pathways for Veillonella parvula lipopoly-saccharide. Clin Vaccine Immunol 2009; 16(12): 1804–1809. DOI: 10.1128/CVI.00310–09De Cruz P., Kang S., Wagner J., Buckley M., Sim WH., Prideaux L. et al. Association between specific mucosa-associated microbiota in Crohn’s disease at the time of resection and subsequent disease recurrence: a pilot study. J Gastroenterol Hepatol 2015; 30(2): 268–278. DOI: 10.1111/jgh.12694De Cruz P., Kang S., Wagner J., Buckley M., Sim WH., Prideaux L. et al. Association between specific mucosa-associated microbiota in Crohn’s disease at the time of resection and subsequent disease recurrence: a pilot study. J Gastroenterol Hepatol 2015; 30(2): 268–278. DOI: 10.1111/jgh.12694Bongaerts G.P., Schreurs B.W., Lunel F.V., Lemmens J.A., Pruszczynski M., Merkx M.A. Was isolation of Veillonella from spinal osteomyelitis possible due to poor tissue perfusion? Med Hypotheses 2004; 63(4): 659–661. DOI: 10.1016/j.mehy.2004.02.052Bongaerts G.P., Schreurs B.W., Lunel F.V., Lemmens J.A., Pruszczynski M., Merkx M.A. Was isolation of Veillonella from spinal osteomyelitis possible due to poor tissue perfusion? Med Hypotheses 2004; 63(4): 659–661. DOI: 10.1016/j.mehy.2004.02.052Rovery C., Etienne A., Foucault C., Berger P., Brouqui P. Veillonella montpellierensis endocarditis. Emerg Infect Dis 2005; 11(7): 1112–1114. DOI: 10.3201/eid1107.041361Rovery C., Etienne A., Foucault C., Berger P., Brouqui P. Veillonella montpellierensis endocarditis. Emerg Infect Dis 2005; 11(7): 1112–1114. DOI: 10.3201/eid1107.041361Wei Y., Li Y., Yan L., Sun C., Miao Q., Wang Q. et al. Alterations of gut microbiome in autoimmune hepatitis. Gut 2020; 69(3): 569–577. DOI: 10.1136/gutjnl-2018–317836Wei Y., Li Y., Yan L., Sun C., Miao Q., Wang Q. et al. Alterations of gut microbiome in autoimmune hepatitis. Gut 2020; 69(3): 569–577. DOI: 10.1136/gutjnl-2018–317836Downes J., Hooper S.J., Wilson M.J., Wade W.G. Prevotella histicola sp. nov., isolated from the human oral cavity. Int J Syst Evol Microbiol 2008; 58(Pt 8): 1788–1791. DOI: 10.1099/ijs.0.65656–0Downes J., Hooper S.J., Wilson M.J., Wade W.G. Prevotella histicola sp. nov., isolated from the human oral cavity. Int J Syst Evol Microbiol 2008; 58(Pt 8): 1788–1791. DOI: 10.1099/ijs.0.65656–0Balakrishnan B., Luckey D., Bodhke R., Chen J., Marietta E., Jeraldo P. et al. Prevotella histicola Protects From Arthritis by Expansion of Allobaculum and Augmenting Butyrate Production in Humanized Mice. Front Immunol 2021; 12: 609644. DOI: 10.3389/fimmu.2021.609644Balakrishnan B., Luckey D., Bodhke R., Chen J., Marietta E., Jeraldo P. et al. Prevotella histicola Protects From Arthritis by Expansion of Allobaculum and Augmenting Butyrate Production in Humanized Mice. Front Immunol 2021; 12: 609644. DOI: 10.3389/fimmu.2021.609644Mangalam A.K., Murray J. Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis. Expert Rev Neurother 2019; 19(1): 45–53. DOI: 10.1080/14737175.2019.1555473Mangalam A.K., Murray J. Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis. Expert Rev Neurother 2019; 19(1): 45–53. DOI: 10.1080/14737175.2019.1555473Shahi S.K., Jensen S.N., Murra A.C., Tang N., Guo H., Gibson-Corley K.N. et al. Human Commensal Prevotella histicola Ameliorates Disease as Effectively as Interferon-Beta in the Experimental Autoimmune Encephalomyelitis. Front Immunol 2020; 11: 578648. DOI: 10.3389/fimmu.2020.578648Shahi S.K., Jensen S.N., Murra A.C., Tang N., Guo H., Gibson-Corley K.N. et al. Human Commensal Prevotella histicola Ameliorates Disease as Effectively as Interferon-Beta in the Experimental Autoimmune Encephalomyelitis. Front Immunol 2020; 11: 578648. DOI: 10.3389/fimmu.2020.578648Liu C.Y., Su W.B., Guo L.B., Zhang Y.W. Cloning, expression, and characterization of a novel heparinase I from Bacteroides eggerthii. Prep Biochem Biotechnol 2020; 50(5): 477–485. DOI: 10.1080/10826068.2019.1709977Liu C.Y., Su W.B., Guo L.B., Zhang Y.W. Cloning, expression, and characterization of a novel heparinase I from Bacteroides eggerthii. Prep Biochem Biotechnol 2020; 50(5): 477–485. DOI: 10.1080/10826068.2019.1709977Kmezik C., Krska D., Mazurkewich S., Larsbrink J. Characterization of a novel multidomain CE15–GH8 enzyme encoded by a polysaccharide utilization locus in the human gut bacterium Bacteroides eggerthii. Sci Rep 2021; 11(1): 17662. DOI: 10.1038/s41598–021–96659-zKmezik C., Krska D., Mazurkewich S., Larsbrink J. Characterization of a novel multidomain CE15–GH8 enzyme encoded by a polysaccharide utilization locus in the human gut bacterium Bacteroides eggerthii. Sci Rep 2021; 11(1): 17662. DOI: 10.1038/s41598–021–96659-zPetersen A.B., Christensen I.A., Rønne M.E., Stender E.G.P., Teze D., Svensson B. et al. 1H, 13C, 15N resonance assignment of the enzyme KdgF from Bacteroides eggerthii. Biomol NMR Assign 2022; 16(2): 343–347. DOI: 10.1007/s12104–022–10102–6Petersen A.B., Christensen I.A., Rønne M.E., Stender E.G.P., Teze D., Svensson B. et al. 1H, 13C, 15N resonance assignment of the enzyme KdgF from Bacteroides eggerthii. Biomol NMR Assign 2022; 16(2): 343–347. DOI: 10.1007/s12104–022–10102–6Domingo M.C., Yansouni C., Gaudreau C., Lamothe F., Lévesque S., Tremblay C. et al. Cloacibacillus sp., a Potential Human Pathogen Associated with Bacteremia in Quebec and New Brunswick. Clin Microbiol 2015; 53(10): 3380–3. DOI: 10.1128/JCM.01137–15Domingo M.C., Yansouni C., Gaudreau C., Lamothe F., Lévesque S., Tremblay C. et al. Cloacibacillus sp., a Potential Human Pathogen Associated with Bacteremia in Quebec and New Brunswick. Clin Microbiol 2015; 53(10): 3380–3. DOI: 10.1128/JCM.01137–15Puón-Peláez X.D., McEwan N.R., Gómez-Soto J.G., Álvarez-Martínez R.C., Olvera-Ramírez A.M. Metataxonomic and Histopathological Study of Rabbit Epizootic Enteropathy in Mexico. Animals (Basel) 2020; 10(6): 936. DOI: 10.3390/ani10060936Puón-Peláez X.D., McEwan N.R., Gómez-Soto J.G., Álvarez-Martínez R.C., Olvera-Ramírez A.M. Metataxonomic and Histopathological Study of Rabbit Epizootic Enteropathy in Mexico. Animals (Basel) 2020; 10(6): 936. DOI: 10.3390/ani10060936

The authors declare that there are no conflicts of interest present.